Please login to the form below

Not currently logged in
Email:
Password:

Santarus begins Zegerid litigation against Par

US-based Santarus, is suing Par Pharmaceutical in the United States District Court for the District of Delaware for an alleged infringement of the patents listed in the FDA's Orange Book for Zegerid (omeprazole/sodium bicarbonate) capsules.

US-based Santarus, is suing Par Pharmaceutical in the United States District Court for the District of Delaware for an alleged infringement of the patents listed in the FDA's Orange Book for Zegerid (omeprazole/sodium bicarbonate) capsules.

The University of Missouri, which is licensor of the patents, has joined Santarus in the litigation as a co-plaintiff.

The lawsuit refers to an Abbreviated New Drug Application (ANDA) filed by Par with the FDA to market a generic version of Zegerid Capsules before the 2016 expiration of three listed US patents (6,645,988, 6,489,346 and 6,699,885).

Santarus filed the lawsuit within the 45 days limit required to prevent the FDA from approving París ANDA for 30 months, or until a district court decision ruling against Santarus.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today....
It’s all about patient outcomes… right?
Lessons from history: a design thinking perspective...
Emma Walmsley 2
30 Women Leaders in UK Healthcare (part 3)
Continuing our special feature on Women Leaders in UK Healthcare...

Infographics